Tdark SS18L2 SS18-like protein 2

Protein Summary

Description

Synovial sarcomas occur most frequently in the extremities around large joints. More than 90% of cases have a recurrent and specific chromosomal translocation, t(X;18)(p11.2;q11.2), in which the 5-prime end of the SS18 gene (MIM 600192) is fused in-frame to the 3-prime end of the SSX1 (MIM 312820), SSX2 (MIM 300192), or SSX4 (MIM 300326) gene. The SS18L2 gene is homologous to SS18.[supplied by OMIM, Jul 2002]

Uniprot Accession IDs

• Q9UHA2
• B2R5L1

Gene Name

• SS18L2

Ensembl ID

• ENST00000011691
• ENSP00000011691
• ENSG00000008324
• ENST00000447630
• ENSP00000401115

Symbol

• KIAA-iso

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
kinase perturbation	0.96
disease perturbation	0.87
transcription factor binding site profile	0.67
tissue sample	0.66
histone modification site profile	0.65

Protein Classes

PANTHER Classes

Protein / Nucleic Acid Binding / Dna Binding Protein / Chromatin/chromatin-binding Protein / Ss18-like Protein 2

DTO Classes

Protein / Nucleic Acid Binding / Dna Binding Protein / Chromatin/chromatin-binding Protein / Ss18-like Protein 2

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 0.96   (req: < 5)

Gene RIFs: 0   (req: <= 3)

Antibodies: 21   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 0.96   (req: >= 5)

Gene RIFs: 0   (req: > 3)

Antibodies: 21   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 4

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0